INmune Bio Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 5
Employees
  • Stock Symbol
  • INMB
Stock Symbol
  • Share Price
  • $16.29
  • (As of Monday Closing)

INmune Bio General Information

Description

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1224 Prospect Street
  • Suite 150 La Jolla
  • San Diego, CA 92037
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

INmune Bio Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.29 $15.22 $7.28 - $29.99 $258M 15.8M 396K -$1.12

INmune Bio Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 155,593 207,419 55,277
Revenue 15 11 0 0
EBITDA (14,585) (12,099) (7,678) (12,440)
Net Income (14,585) (12,099) (7,678) (12,440)
Total Assets 65,874 40,656 24,470 17,363
Total Debt 139 160 168 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

INmune Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore INmune Bio‘s full profile, request access.

Request a free trial

INmune Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that r
Other Healthcare Technology Systems
San Diego, CA
5 As of 2020
000.00
00.00 0000-00-00
00000000 000.00

00000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ex
0000000000000
South San Francisco, CA
000 As of 0000
00000
0.00 0000-00-00
00000000 00000

0000000

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur s
0000 00000000
San Francisco, CA
0 As of 0000
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

INmune Bio Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allogene Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 Formerly Accelerator/Incubator backed San Francisco, CA 0 000000&0
0000 000000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000 00000000000 Corporation New York, NY 0000000000
0000000 000 Corporation New York, NY 00 00000 00000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

INmune Bio Executive Team (3)

Name Title Board Seat Contact Info
Raymond Tesi MD Chief Executive Officer & Chairman
David Moss Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Mark Lowdell Ph.D Chief Scientific Officer
To view INmune Bio’s complete executive team members history, request access »

INmune Bio Board Members (7)

Name Representing Role Since
David Szymkowski Ph.D INmune Bio Board Member 000 0000
Edgardo Baracchini Ph.D Self Board Member 000 0000
Kelly Ganjei Self Board Member 000 0000
Raymond Tesi MD INmune Bio Chief Executive Officer & Chairman 000 0000
Scott Juda INmune Bio Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

INmune Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial